FirstGroup (OTCMKTS:FGROY) vs. Zealand Pharma A/S (OTCMKTS:ZLDPF) Head-To-Head Survey

Zealand Pharma A/S (OTCMKTS:ZLDPF) and FirstGroup (OTCMKTS:FGROY) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, institutional ownership, risk, dividends and earnings.

Profitability

This table compares Zealand Pharma A/S and FirstGroup’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zealand Pharma A/S	-1,725.03%	-15.24%	-13.77%
FirstGroup	N/A	N/A	N/A

Volatility and Risk

Zealand Pharma A/S has a beta of 0.88, indicating that its stock price is 12% less volatile than the S&P 500. Comparatively, FirstGroup has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations for Zealand Pharma A/S and FirstGroup, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zealand Pharma A/S	0	0	2	1	3.33
FirstGroup	0	0	0	0	0.00

Earnings and Valuation

This table compares Zealand Pharma A/S and FirstGroup”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zealand Pharma A/S	$9.09 million	764.00	-$102.18 million	($2.36)	-41.43
FirstGroup	$5.93 billion	0.24	-$19.99 million	N/A	N/A

FirstGroup has higher revenue and earnings than Zealand Pharma A/S.

Summary

FirstGroup beats Zealand Pharma A/S on 6 of the 10 factors compared between the two stocks.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.

About FirstGroup

FirstGroup plc provides public transport services in the United Kingdom. The company operates through First Bus and First Rail segments. The First Bus segment offers local bus services with a fleet of approximately 4,800 buses in the United Kingdom. The First Rail segment operates a passenger rail network that provides long-distance, commuter, regional, and sleeper services through a portfolio of Great Western Railway, South Western Railway, and Avanti West Coast franchises; and hull trains and Lumos. FirstGroup plc was founded in 1986 and is based in London, the United Kingdom.